Answers are grounded in this paper and cite their sources.
30 patients with oestrogen-escaped carcinoma of the prostate have been treated with estramustine phosphate (Estracyt). 27% showed a partial objective response and 33% had a subjective response. The terms used for defining a response are challenged and it is recommended that comparative controlled trials are necessary to judge the place of this drug in the management of advanced prostatic cancer.
No takes yet. Share an insight, caveat, or question.
CHISHOLM et al. (1977) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: